72
Participants
Start Date
May 28, 2020
Primary Completion Date
February 13, 2021
Study Completion Date
February 13, 2021
APL-9
Complement (C3) Inhibitor
Vehicle Control
Normal saline of equal volume to active arm
Columbia University, New York
University at Buffalo, Buffalo
Baptist Medical Center Beaches, Jacksonville Beach
Norton Women's and Children's Hospital, Louisville
Norton Audobon Hospital, Louisville
Westchester General Hospital, Miami
Lutheran Health Physicians, Fort Wayne
Ascension Providence Hospital, Southfield
University of Iowa Hospitals and Clinics, Iowa City
Loyola University Medical Center, Maywood
Northwestern University, Feinberg School of Medicine, Chicago
Cambridge Medical Trials, Alexandria
Texas A&M College of Medicine - Scott and White, Temple
University of California at San Francisco - Fresno, Fresno
California Pacific Medical Center, San Francisco
Rutgers University - Robert Wood Johnson Medical School, New Brunswick
Hospital Angelina Caron, Campina Grande do Sul
Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Hospital São Lucas da PUCRS, Porto Alegre
UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP, Botucatu
Hospital Estadual Mario Covas, Santo André
CEMEC - Centro Multidisciplinar de Estudos Clinicos LTDA EPP, São Bernardo do Campo
Hospital Alemao Oswaldo Cruz, São Paulo
Hospital Santa Marcelina, São Paulo
Lead Sponsor
Apellis Pharmaceuticals, Inc.
INDUSTRY